Parathyroid cancer is a rare malignant neoplasm that forms from the cells of the parathyroid glands. These glands are responsible for regulating the level of calcium in the blood, the secretion of parathyroid hormone, which makes them important for maintaining homeostasis. The pathology can manifest itself in the form of atypical cells that are capable of metastasizing to various organs, which significantly complicates diagnosis and treatment. Despite the fact that parathyroid cancer is much less common than tumors of other endocrine organs, its clinical manifestations require special attention from both specialists and patients.
History of the disease and interesting historical facts
The history of parathyroid cancer research dates back to the early 20th century, when the first cases of this disease were described in scientific literature. In 1910, Austrian surgeon Hans Rosenberg first paid attention to the morphological features of parathyroid tumors. However, it was not until 1936 that the first successful surgical intervention on the affected parathyroid gland was performed, which marked the beginning of clinical practice in the treatment of this disease. The uniqueness of parathyroid cancer is that it is jointly studied by both endocrinologists and oncologists, which contributes to an integrated approach to diagnosis and therapy. In addition, in recent decades, there has been an increase in interest in the molecular genetic characteristics of this disease, which opens up new horizons for understanding its pathogenesis.
Epidemiology
Statistics on the occurrence of parathyroid cancer confirm its rare occurrence, accounting for only 0.1 to 0.5% of all cases of malignant neoplasms. According to various studies, this pathology is diagnosed mainly in women, and the ratio of 男:women is 1:3. The age range of patients most often varies from 50 to 70 years. According to a study conducted in 2020 in US clinics, about 200-300 new cases of parathyroid cancer are registered annually, which imposes the need to develop more effective methods for early diagnosis. There is also an increase in the incidence of parathyroid cancer among people with hereditary syndromes, such as multiple endocrine neoplasia (MEN) type 2.
Genetic predisposition to this disease
Genetic aspects of parathyroid cancer play a significant role in its development, especially in hereditary forms. The main genes involved are RET, MEN1 and CDKN1B, mutations of which can lead to dysfunction of the parathyroid glands and an increased risk of malignant tumors. For example, mutations in the RET gene are associated with multiple endocrine neoplasia syndrome, which increases the likelihood of developing parathyroid cancer to 50%. It has also been established that polymorphisms in other genes responsible for calcium metabolism may be associated with an increased risk of this disease. Modern research in the field of genomic medicine is aimed at identifying new genetic markers, which can contribute to more accurate diagnostics and the development of personalized treatments.
Risk factors for the development of this disease
There are several factors that contribute to the development of parathyroid cancer. These include:
- Heredity - a family history of parathyroid cancer or multiple endocrine neoplasia syndromes.
- Radiation exposure - especially if there is a history of cervical radiation.
- Thyroid diseases - such as hyperthyroidism or nodular goiter.
- Age and gender - higher predisposition in women over 50 years of age.
- Climate and environmental factors - some regions have higher incidence rates.
Despite the presence of these factors, it is important to remember that, having one or more of them, not every patient will develop this disease, which emphasizes the complexity and multifaceted nature of its pathogenesis.
Diagnosis of this disease
Diagnosis of parathyroid cancer involves several steps, including history taking, clinical evaluation, and a series of laboratory and radiological tests. Key symptoms may include:
- Enlargement of the parathyroid gland (parathyroid adenoma)
- Symptoms of hypercalcemia include thirst, frequent urination, muscle cramps.
- Neck pain or difficulty swallowing and breathing.
Laboratory tests include measuring calcium and parathyroid hormone (PTH) levels in the blood. Radiological examinations such as neck ultrasound and scintigraphy help visualize tumor structures. It is important to conduct a differential diagnosis with other diseases, such as adenomas of other parts of the endocrine system, which requires the participation of endocrinologists and oncologists.
Treatment
Treatment of parathyroid cancer involves a comprehensive approach, which includes:
- Surgery is the main treatment and aims to remove the tumor and affected tissue.
- Pharmacotherapy - used in case of metastasis, may include calcitonin and bisphosphonates to control calcium levels.
- Other treatments, such as radiation therapy and targeted therapy, are used very rarely but may be used in research studies.
The effectiveness of treatment directly depends on the stage of the disease and the presence of metastases, so it is important to conduct early diagnosis and regular examinations.
List of medications used to treat this disease
The list of drugs used to treat parathyroid cancer includes:
- Calcitonin - helps reduce calcium levels in the blood.
- Bisphosphonates (eg, zoledronic acid) - used to treat hypercalcemia.
- Selective inhibitors - including some drugs that help block tumor growth.
- Hormonal drugs, if we are talking about concomitant diseases.
Referral to specialized centers that provide targeted therapy and research into new drugs can significantly increase the chances of successful treatment.
Disease monitoring
Monitoring a patient with parathyroid cancer involves regular examinations and tests to monitor calcium and PTH levels. Diagnostic checkpoints may include:
- Post-procedural monitoring at 1, 3 and 6 months after surgery.
- One-year follow-up when the patient's condition is stable.
- Imaging studies if recurrence of the disease is suspected.
The prognosis for early diagnosis of parathyroid cancer is generally good, but recurrences and complications may occur in 20-30% patients.
Age-related features of the disease
Parathyroid cancer can manifest itself with different symptoms and stages depending on the patient's age. In older people, the disease is often diagnosed at later stages due to the lack of specific symptoms. In children, parathyroid cancer is extremely rare, but if it occurs, it is often associated with hereditary diseases. In young people, the pathology, as a rule, has a better prognostic significance and can often be cured in the early stages.
Questions and Answers
- What are the main symptoms of parathyroid cancer? The main symptoms include enlargement of the parathyroid gland, symptoms of hypercalcemia, neck pain, difficulty swallowing.
- Who is at risk for developing parathyroid cancer? Those at risk include people with a hereditary predisposition, women over 50 years of age, and patients with thyroid disease.
- How is this disease diagnosed? Diagnosis includes clinical examination, laboratory tests, ultrasound and radiological examinations.
- What is the prognosis after treatment for parathyroid cancer? The prognosis depends on the stage of the disease at the time of diagnosis; early stages have a favorable prognosis.
- What is the most effective treatment for this condition? The main method of treatment is surgical intervention, which, if necessary, can be supplemented with drug therapy.
